Previous Close | 15.36 |
Open | 15.76 |
Bid | 14.81 x 900 |
Ask | 15.58 x 1000 |
Day's Range | 14.61 - 15.79 |
52 Week Range | 8.80 - 36.49 |
Volume | |
Avg. Volume | 533,106 |
Market Cap | 419.777M |
Beta (5Y Monthly) | 1.18 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.11 |
Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.64 |
Subscribe to Yahoo Finance Plus to view Fair Value for BTAI
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal trial evaluating at-home use of BXCL501 for the acute treatment of agitation in bipolar and schizophrenia patients planned to initiate in 2H 2022 following recent Type B meeting with FDA Top-line data from TRANQUILITY II pivotal trial for agitation associated with Alzheimer’s disease expected in 1H 2023; TRANQUIL
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 a
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161 NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelli